|
||
ZalcitabineZalcitabine , also called dideoxycytidine, is a nucleoside analog reverse transcriptase inhibitor sold under the trade name Hivid®. The recommended dosage is 0.750 mg every 8 hours, as part of a combination regimen.Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events. For these reasons it is now rarely used to treat human immunodeficiency virus . (From the Wikpedia article Zalcitabine.) Download PDFImage ResultsLoading...
BioPortfolio Ltd. offers e-mail and postal lists for Zalcitabine scientists - we have details of around 129 individuals working on Zalcitabine . This page has been viewed 135 times Recent Search Terms used to find this page: zalcitabine | . Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed. Search for Zalcitabine across BioPortfolio, or bestselling Zalcitabine books or recently published Zalcitabine books . Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. | |||||||||||||||||||||||||||||||||||||||||||||||||||
Nothing in this website should be used in place of personal medical
advice from your own qualified medical practitioner. See
User
Agreement |
All rights reserved. All other trademarks recognized. |
|
|